Contact
searchSearch
HMP Global
Login

News

News
STRIDE-Based Regimens Plus TACE Improve Outcomes vs TACE Alone in Embolization-Eligible Hepatocellular Carcinoma
07/07/2026
Stephanie Holland
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3...
07/07/2026
Oncology
Stephen Lam Chan, MD
Videos
Adjuvant Pembrolizumab Fails to Improve Recurrence-Free Survival in Hepatocellular Carcinoma
01/26/2026
Stephen Lam Chan, MD
Stephen Lam Chan, MD, discusses results from the phase 3 KEYNOTE-937 trial showing that adjuvant pembrolizumab did not improve recurrence-free survival following curative-intent surgery or local ablation for hepatocellular carcinoma,...
Stephen Lam Chan, MD, discusses results from the phase 3 KEYNOTE-937 trial showing that adjuvant pembrolizumab did not improve recurrence-free survival following curative-intent surgery or local ablation for hepatocellular carcinoma,...
Stephen Lam Chan, MD, discusses...
01/26/2026
Oncology
Farshid Dayyani, MD, PhD
Videos
Combination Immunotherapy and TACE Demonstrate Encouraging Activity in Liver-Limited Hepatocellular Carcinoma
01/14/2026
Farshid Dayyani, MD, PhD
Farshid Dayyani, MD, PhD, discusses results from a phase 2 trial showing that combination immunotherapy, targeted therapy, and transarterial chemoembolization achieved encouraging response rates and enabled curative-intent resection in...
Farshid Dayyani, MD, PhD, discusses results from a phase 2 trial showing that combination immunotherapy, targeted therapy, and transarterial chemoembolization achieved encouraging response rates and enabled curative-intent resection in...
Farshid Dayyani, MD, PhD,...
01/14/2026
Oncology
Farshid Dayyani, MD, PhD
Videos
Immunotherapy, TACE, and Cabozantinib in Unresectable Hepatocellular Carcinoma
01/14/2026
Farshid Dayyani, MD, PhD
Farshid Dayyani, MD, PhD, discusses a phase 2 study evaluating induction ipilimumab plus nivolumab followed by transarterial chemoembolization and consolidation with cabozantinib plus nivolumab in patients with unresectable hepatocellular...
Farshid Dayyani, MD, PhD, discusses a phase 2 study evaluating induction ipilimumab plus nivolumab followed by transarterial chemoembolization and consolidation with cabozantinib plus nivolumab in patients with unresectable hepatocellular...
Farshid Dayyani, MD, PhD,...
01/14/2026
Oncology
Nadine Abi-Jaoudeh, MD
Videos
TATE Plus Nivolumab Demonstrates Activity in Immunotherapy-Refractory Hepatocellular Carcinoma
01/13/2026
Nadine Abi-Jaoudeh, MD
Nadine Abi-Jaoudeh, MD, discusses results from a phase 2 trial showing that transarterial tirapazamine embolization combined with nivolumab produced encouraging and durable responses in patients with immunotherapy-refractory advanced...
Nadine Abi-Jaoudeh, MD, discusses results from a phase 2 trial showing that transarterial tirapazamine embolization combined with nivolumab produced encouraging and durable responses in patients with immunotherapy-refractory advanced...
Nadine Abi-Jaoudeh, MD,...
01/13/2026
Oncology
News
First-Line Nivolumab Plus Ipilimumab for Patients With Unresectable Hepatocellular Carcinoma: CheckMate 9DW 4-Year Follow-Up
01/12/2026
Stephanie Holland
Updated results from the phase 3 CheckMate 9DW trial show that first-line nivolumab plus ipilimumab continues to demonstrate sustained clinical efficacy with a manageable safety profile among patients with unresectable hepatocellular...
Updated results from the phase 3 CheckMate 9DW trial show that first-line nivolumab plus ipilimumab continues to demonstrate sustained clinical efficacy with a manageable safety profile among patients with unresectable hepatocellular...
Updated results from the phase 3...
01/12/2026
Oncology
News
First-Line Nivolumab Plus Ipilimumab for Patients With Unresectable Hepatocellular Carcinoma: CheckMate 9DW 4-Year Follow-Up
01/12/2026
Stephanie Holland
Updated results from the phase 3 CheckMate 9DW trial show that first-line nivolumab plus ipilimumab continues to demonstrate sustained clinical efficacy with a manageable safety profile among patients with unresectable hepatocellular...
Updated results from the phase 3 CheckMate 9DW trial show that first-line nivolumab plus ipilimumab continues to demonstrate sustained clinical efficacy with a manageable safety profile among patients with unresectable hepatocellular...
Updated results from the phase 3...
01/12/2026
Oncology
FDA Approval
FDA Approves Y-90 Resin Microspheres for Patients With Unresectable Hepatocellular Carcinoma
07/08/2025
Stephanie Holland
Based on interim results from the DOORwaY90 trial, the FDA has approved Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.
Based on interim results from the DOORwaY90 trial, the FDA has approved Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.
Based on interim results from...
07/08/2025
Oncology
Conference Coverage
Atezolizumab Plus Bevacizumab Added to On-Demand TACE Improved Survival Outcomes for Patients With Unresectable Hepatocellular Carcinoma
07/03/2025
Allison Casey
According to the TALENTACE trial, the addition of atezolizumab and bevacizumab to on-demand transarterial chemoembolization improved the TACE–progression-free survival for treatment-naïve patients with unresectable hepatocellular carcinoma...
According to the TALENTACE trial, the addition of atezolizumab and bevacizumab to on-demand transarterial chemoembolization improved the TACE–progression-free survival for treatment-naïve patients with unresectable hepatocellular carcinoma...
According to the TALENTACE...
07/03/2025
Oncology
Conference Coverage
Atezolizumab Plus Bevacizumab Added to On-Demand TACE Improved Survival Outcomes for Patients With Unresectable Hepatocellular Carcinoma
07/03/2025
Allison Casey
According to the TALENTACE trial, the addition of atezolizumab and bevacizumab to on-demand transarterial chemoembolization improved the TACE–progression-free survival for treatment-naïve patients with unresectable hepatocellular carcinoma...
According to the TALENTACE trial, the addition of atezolizumab and bevacizumab to on-demand transarterial chemoembolization improved the TACE–progression-free survival for treatment-naïve patients with unresectable hepatocellular carcinoma...
According to the TALENTACE...
07/03/2025
Oncology

Recent News

News
NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera
09/22/2026
Stephanie Holland
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines...
09/22/2026
Oncology
News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer
09/22/2026
Stephanie Holland
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3...
09/22/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
09/21/2026
Emily Estrada
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3...
09/21/2026
Oncology
FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer
09/16/2026
Stephanie Holland
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3...
09/16/2026
Oncology
FDA Alerts
FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access
09/16/2026
Stephanie Holland
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing...
09/16/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use